AMRN: Keep an eye on shares of Amarin this week.

After flying higher on news late last year that one AMR101 Phase III trial had produced positive trial results - and then news again in January that the ongoing ANCHOR Phase III trial would be completed ahead of schedule, the company announced during the early-hours on Monday that the results are in fact in for ANCHOR, and those results are all positive.

The company announced that all endpoints were met and that AMR101 is primed to become a first-in-class treatment for high triglycerides.

I'm not convinced that the volitility is over for AMRN, as the current trend in the biotech sector is to see down trading after a company releases good news, but the long term certainly looks bright.

I expand on these thoughts in a pending Seeking Alpha release.

Disclosure: No position.

Add a Comment